Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-881-5 | CAS number: 29820-13-1
Read-across from supporting substance (structural analogue or surrogate): No reliable data is available on the repeated dose toxicity of CaTG. However, the subchronic toxicity of sodium thioglycolate was evaluated by oral and dermal administrations.In an oral repeated dose toxicity study compliant with OECD guideline 408, sodium thioglycolate (NaTG) was administered by gavage to Sprague-Dawley. The main effects, fully reversible, seemed to be related to the inhibition of the β-oxidation of fatty acids. The NOAEL was established at 20mg/kg bw/d and the NOEL at 7 mg/kg bw/d. In a repeated dose dermal toxicity study using a method comparable to OECD guideline 411, sodium thioglycolate was administered to Fischer 344 rats and B6C3F1 mice. All animals survived the 13 weeks administration. The only treatment-related effect was skin irritation at the site of application. The Lowest-Observed-Effect-Levels (LOELs) at the application site were 11.25 and 45 mg/kg bw/d in rats and mice, respectively, based on skin irritation. There was no No-Observed-Effect-Level (NOEL) at the application site. The NOAELs for systemic toxicity can be estimated to be higher than 180 and 360 mg/kg bw/d in rats and mice, respectively.No data are available on inhalation toxicity after repeated exposure to thioglycolic acid or its salts.
No reliable data are available on the repeated dose toxicity of CaTG. However, the subchronic toxicity of sodium thioglycolate (NaTG) was evaluated by oral and dermal administrations and can be used as a surrogate (read-across from supporting substance).
The potential toxicity of NaTG was evaluated following repeated oral administration for 13 weeks, according to OECD Guideline 408. The test item was administered daily by gavage to Sprague-Dawley rats (10 Males and 10 Females), at the dose-levels of 0, 7, 20, 60 mg/kg/d during 90 days. An additional group of 6 male and 6 female rats was concurrently treated with the vehicle and high dose level; this group was retained following the final exposure for a further 4 weeks to assess the reversibility of any adverse findings.
Body weights were recorded pre-test, weekly and at death or prior to necropsy. Animals were observed twice daily for mortality ant clinical signs. Detailed clinical observations were made once before the beginning of the treatment period, and then once a week until the end of the study. During week 11, this examination was included in the detailed clinical observation of the Functional Observation Battery for all animals except recovery animals. Whole blood, serum and plasma were sampled just prior to necropsy and analysed for related haematological and clinical chemistry parameters. All animals were examined for gross pathology, and organs were weighed and submitted to histopathology.
At 60 mg/kg/day, one female was prematurely sacrificed on day 14 due to humane reasons, and one male was found dead on day 90. Death was attributed to the test item treatment. At 60 mg/kg/day, changes were observed; they were also noted in the animals sacrificed on schedule. These changes were found in the heart of the dead male, the kidneys of the female sacrificed for humane reasons, and the liver and thymus of both animals. Hypersalivation, piloerection, abnormal growth of teeth, alopecia and/or areas of thinned hair were transiently observed in some of the surviving animals. At laboratory investigations, marked panleucopenia was noted (all the white blood cell subtypes were affected), with high mean red blood cell count, hemoglobin concentration, packed cell volume and mean prothrombin time for males and females. Hypoglycemia was noted in males and females, associated with high urea (males and females) and creatinine (males only) levels and low chloride levels (only female). Other blood perturbation were observed (High fat acid level -in males and females- high aspartate aminotransferase -males only- and high ALAT -males and females). Thioglycolate-related changes were also noted in the liver of males and females, the heart of males and the kidneys of females. Considering the treatment-related effects observed at 60 mg/kg bw/d -mortality, microscopic changes in the heart of males, kidney of females, and liver of males, and the changes in some haematological and blood chemistry parameters - this dose level is regarded as clearly toxic dose level.
At 20 mg/kg/day, in the absence of treatment related histopathological changes, the reversible modifications of some biochemical parameters observed in the females are not considered to be adverse. At 7 mg/kg/day, the test item did not elicit any signs of toxicity. Consequently, under the experimental conditions, the No-Observed-Adverse-Effect-Level (NOAEL) is 20 mg/kg/day (Rousseau, 2008).
NaTG (99% pure) was administered dermally to F344/N rats and B6C3F1mice (10/sex/dose level) following a protocol comparable to the OECD guideline 411. Rats and mice were given NaTG in a vehicle of 95% ethanol:deionized water (1:1) by dermal application 5 days per week, for 13 weeks. Doses were appliedin a fixed dose volume of 0.5 ml/kg bw to rats or 0.2 ml/kg bw to mice. Rats were administered 0, 11.25, 22.5, 45, 90, or 180 mg NaTG/kg bw/d and mice 0, 22.5, 45, 90, 180 or 360 mg NaTG/kg bw/d.In addition, 2 groups of 10 rats per sex/group were dosed with 0 or 180 mg/kgbw/d for 21 days and used for clinical chemistry and hematology estimations on day 4 and day 21 and then disposed of without further examination. Throughout the study, the animals were checked twice a day for mortality and clinical signs. Formal clinical observations were performed and recorded weekly. Body weight and food consumption were recorded weekly. Clinical chemistry and hematology was performed on the main groups of rats at termination, and hematology on the mice at termination. Heart, kidney, liver, lung, spleen, tests, thymus and thyroid/parathyroid weights were measured at termination, with a complete histopathologic examination inclusive of gross lesions of the high dose and control groups. Food consumption and clinical chemistry parameters including 3-hydroxybutyrate, free fatty acids and total cholesterol were also measured.
In the rats, all animals survived the 13-week administration. A slight decrease of the mean body weight gain was observed in males treated with 90 and 180 mg/kg bw/d, respectively. The mean food consumption was not affected by the treatment.Significant clinical observations noted in both sexes were limited to dermal irritation, thickened skin and ulcerations at the site of application. In males and females, the incidence of dermal irritation at the site of application was 10/10 for all five-treatment groups. Thickening of the skin at the site of application was observed in 1 and 2 males from the 90 and 180 mg/kgbw/d dose groups andin 3, 10 and 10 females from the 45, 90 and 180mg/kgbw/d dose groups, respectively. Ulceration at the site of application was observed in 1, 1, 5 and 8 male rats from the 11.25, 22.5, 90 and 180 mg/kgbw/d dose groups and 10 females from each of the 90 and 180 mg/kgbw/d dose groups, respectively. All other clinical observations noted during the study were not considered to be biologically significant.
There were slight, but statistically significant, changes in the relative kidneys weight in males at 90 and 180 mg/kg bw/d and in females at 180 mg/kg bw/d, in the absolute and relative liver weights in males at 45 mg/kgbw/d, in the relative spleen weight in males at 90 mg/kg bw/d, in the relative testes weight at 90 and 180 mg/kg bw/d and in the thyroid/parathyroid relative weight in females at 22.5 mg/kg bw/d, but these effects were not dose responsive or considered to be biologically significant.
There were limited statistically significant differences at termination in some blood chemistry and hematology results when compared to the control group, but these effects were not dose responsive nor considered to be biologically significant.
The only treatment related gross and microscopic lesions were at site of application with epidermal and sebaceous gland hyperplasia, and hyperkeratosis with severity comparable between all treated groups. There were no other treatment related microscopic lesions. Thus, no target organ for toxicity was identified (other than skin at site of application).
The Lowest-Observed-Effect-Level (LOEL) at the application site was 11.25 mg/kg bw/d based on histopathologic examination. There was no No-Observed-Effect-Level (NOEL) at the application site. The NOAEL for systemic toxicity can be estimated to be higher than 180 mg/kg bw/d.
In the mice, all animals survived the 13 weeks administration. Body weights and food consumption were not affected by the treatment in either sex during the course of the study. The only clinical observation related to treatment was skin irritation at site of application in 6/10 males at 360 mg/kg bw/day but not in females.
There was a slight increase of the absolute and relative heart weight at 180 and 360 mg/kg bw/d male and female, of the absolute kidney weight in females at 180 and 360 mg/kg bw/d, and of the absolute and relative liver weight in males at 180 and 360 mg/kg bw/d and in females at all doses from 45 mg/kg bw/d upwards.
Haematology showed no biologically significant changes in males, but in females there was some small decrease, in red blood cells at 22.5, 45, 180 and 360 mg/kg bw/d and hemoglobin levels at 22.5, 45, and 360 mg/kg bw/d.
There were no significant gross lesions. On microscopic histopathology, skin lesions were observed at the site of application in males and females at all dose levels, with the exception of the 22.5 mg/kgbw/ddose group males with minimal to moderate hyperplasia of the epidermis accompanied, in some animals, by sebaceous gland hyperplasia, hyperkeratosis, dermal inflammation and/or parakeratosis. The severity of the changes was comparable between all treatment groups in both the male and female mice. Thus, no target organ for toxicity was identified (other than skin at the site of application).
The Lowest-Observed-Effect-Level (LOEL) at the application site was 45 mg/kg bw/d based on histopathologic examination. The No-Observed-Effect-Level (NOEL) at the application site was 22.5 mg/kg bw/d. The NOAEL for systemic toxicity can be estimated to higher than 360 mg/kg bw/d.
There is no information available on inhalation toxicity after repeated exposure to thioglycolic acid or its salts.
The substance is not classified for STOT since the mortality observed at 60 mg/kg bw/day is already covered by the classification for acute oral toxicity. Sub-lethal effects that would warrant a STOT classification were not found.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again